SCHEMBL16362111

SCHEMBL16362111

c1ccc(-c2ccccc2OP(c2cccc3c2OCC3)c2cccc3c2OCC3)c(OP(c2cccc3c2OCC3)c2cccc3c2OCC3)c1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.39
SLC6A4 P31645 4/20 0.36
SLC6A2 P23975 3/20 0.36
HRH1 P35367 1/20 0.36
SLC6A3 Q01959 1/20 0.36
MAPT P10636 2/20 0.33
RAB9A P51151 2/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP3A4 P08684 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
GRM2 Q14416 1/20 0.31
NPC1 O15118 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2C19 P33261 1/20 0.31
KCNH2 Q12809 1/20 0.31
HTR1A P08908 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17875581 0.79 PARP1 (0.41) PARP1SLC6A4SLC6A2HRH1SLC6A3
SCHEMBL17875568 0.79 DRD1 (0.41) PARP1SLC6A4SLC6A2HRH1SLC6A3
SCHEMBL16362115 0.79 MAPT (0.38) PARP1SLC6A4SLC6A2HRH1SLC6A3
SCHEMBL17875571 0.76 PARP1 (0.44) PARP1SLC6A4SLC6A2HRH1SLC6A3
SCHEMBL16362124 0.76 PARP1 (0.41) PARP1SLC6A4SLC6A2HRH1SLC6A3
SCHEMBL17875566 0.76 PARP1 (0.41) PARP1SLC6A4SLC6A2HRH1SLC6A3
SCHEMBL16325179 0.73 HTR2A (0.40) PARP1SLC6A4SLC6A2HRH1SLC6A3
SCHEMBL16361856 0.73 HTR2A (0.40) PARP1SLC6A4SLC6A2HRH1SLC6A3
SCHEMBL1833547 0.73 PARP1 (0.50) PARP1SLC6A4SLC6A2HRH1SLC6A3
SCHEMBL17876322 0.72 PARP1 (0.40) PARP1SLC6A4SLC6A2HRH1SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9579641-B2 Aryl phosphines with fused ring ortho-alkoxy substitution DOW GLOBAL TECHNOLOGIES LLC (US) 2017-02-28 US disclosed
US-9579641-B2 Aryl phosphines with fused ring ortho-alkoxy substitution DOW GLOBAL TECHNOLOGIES LLC (US) 2017-02-28 US disclosed
US-20160184811-A1 ARYL PHOSPHINES WITH FUSED RING ORTHO-ALKOXY SUBSTITUTION DOW GLOBAL TECHNOLOGIES LLC (US) 2016-06-30 US disclosed
US-20160184811-A1 ARYL PHOSPHINES WITH FUSED RING ORTHO-ALKOXY SUBSTITUTION DOW GLOBAL TECHNOLOGIES LLC (US) 2016-06-30 US disclosed
WO-2014205025-A1 ARYL PHOSPHINES WITH FUSED RING ORTHO-ALKOXY SUBSTITUTION DOW GLOBAL TECHNOLOGIES LLC (US) 2014-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160184811-A1 ARYL PHOSPHINES WITH FUSED RING ORTHO-ALKOXY SUBSTITUTION ALK, PHOSPHO1, MPL PARP1 3058/4885SLC6A4 2286/4885SLC6A2 2602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.